A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

This Phase 1 study tests a new radioactive cancer drug called [225Ac]-FPI-2068, which uses radioactive actinium to deliver targeted radiation directly to solid tumor cells. It is designed for adults with advanced cancers that have not responded to standard therapies. **You may be eligible if...** - You have a confirmed solid tumor (cancer) that has spread, cannot be surgically removed, or has returned after prior treatment - Your cancer has no effective standard treatment options remaining - You have measurable disease on imaging - Your overall health status is good (ECOG 0 or 1) - Your organ function is adequate **You may NOT be eligible if...** - You have previously received any radioactive drug (radiopharmaceutical) therapy - You received recent radiation treatment (within 28 days) - You have an uncontrolled fluid buildup around the lungs, heart, or abdomen - You have untreated or actively growing brain metastases - You cannot undergo the required imaging procedures - You have not recovered from prior cancer treatment side effects Talk to your doctor to see if this trial is right for you.